X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MM-120 (lysergide D-tartrate) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at 5-HT2A receptors. It is being evaluated for the treatment of generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 03, 2023
Details:
MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD).
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD)
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Lysergic acid diethylamide is under development for the treatment of anxiety disorders, major depressive disorder, and unspecified cancer. The therapeutic candidate acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A).
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2023
Details:
By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA (3,4-methylenedioxymethamphetamine) and MDA.
Lead Product(s): Lys-MDA
Therapeutic Area: Neurology Product Name: R(-)-MDMA
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Basel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
MindMed’s lead drug candidate, MM-120, is a proprietary, pharmaceutically optimized form of LSD D-Tartrate that is separate from the free-base form of LSD (CAS -50-37-3).
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Basel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
